Skip to main content
Figure 1 | Journal of Hematology & Oncology

Figure 1

From: Administration of imatinib after allogeneic hematopoietic stem cell transplantation may improve disease-free survival for patients with Philadelphia chromosome-positive acute lymphobla stic leukemia

Figure 1

Cumulative incidence of relapse for patients in imatinib and non-imatinib groups, post-HCT. The relapse rate was calculated by taking into account the competing risk of death due to other complications. The cumulative incidence of relapse was significantly lower in imatinib compared with non-imatinib treated groups (10.18% vs 33.05%, p = 0.016).

Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us